NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36819
Issuer: Spark Therapeutics, Inc.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 3737 Market Street
Philadelphia,
PENNSYLVANIA
19104
Telephone number: 888-772-7560
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2019-12-17ByTara PettaDirector
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Onconetix (NASDAQ:ONCE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Onconetix.
Onconetix (NASDAQ:ONCE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Onconetix.

Notícias Spark Therapeutics, Inc.

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Sexta, 26 de Abril de 2024 (2 meses atrás) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Quinta, 11 de Abril de 2024 (2 meses atrás) • Edgar (US Regulatory)
Form 8-K - Current report
Segunda, 8 de Abril de 2024 (2 meses atrás) • Edgar (US Regulatory)
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Segunda, 1 de Abril de 2024 (3 meses atrás) • Edgar (US Regulatory)
Form 8-K/A - Current report: [Amend]
Quarta, 13 de Março de 2024 (3 meses atrás) • Edgar (US Regulatory)
Form 8-K/A - Current report: [Amend]
Terça, 27 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form 3 - Initial statement of beneficial ownership of securities
Sexta, 16 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form S-1 - General form for registration of securities under the Securities Act of 1933
Quarta, 14 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form PRE 14A - Other preliminary proxy statements
Quarta, 14 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form 8-K - Current report
Terça, 13 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form 8-K - Current report
Segunda, 12 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory)
Form S-8 - Securities to be offered to employees in employee benefit plans
Quinta, 1 de Fevereiro de 2024 (5 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Spark Therapeutics, Inc.